Permira subsidiary Neuraxpharm acquires two product portfolios from Sanofi

Frank­furt a. M. — The Neur­ax­ph­arm Group has acqui­red two product port­fo­lios from Sanofi, which are marke­ted globally in over 50 count­ries. With the pending acqui­si­tion, Neur­ax­ph­arm aims to streng­then its posi­tion as a leading Euro­pean specialty phar­maceu­ti­cal company focu­sed on central nervous system disor­ders and expand its global foot­print. The acqui­si­tion of the port­fo­lios will increase Neuraxpharm’s annual gross sales to appro­xi­m­ately €0.6 billion. — Inter­na­tio­nal law firm Clif­ford Chance advi­sed Neur­ax­ph­arm Group on the acqui­si­tion of the two product port­fo­lios from Sanofi.

The initial port­fo­lio includes a range of products targe­ting central nervous system disor­ders, cove­ring the areas of psych­ia­try and neuro­logy — inclu­ding the drugs Nozinan, Tran­xene, Tiapri­dal, Dogma­til and Largac­til. The second port­fo­lio includes Topal­gic and Tren­tal, two products for the treat­ment of pain and vascu­lar dise­a­ses. The drugs are used in a variety of pati­ents with diffe­rent condi­ti­ons, inclu­ding depres­sion, anxiety, psycho­sis, alco­hol depen­dence, myasthe­nia gravis and Parkinson’s dise­ase. Both product port­fo­lios comprise 17 mole­cu­les marke­ted under 38 brands.

About Neur­ax­ph­arm

Neur­ax­ph­arm is a port­fo­lio group of the private equity fund Perm­ira. Clif­ford Chance had alre­ady advi­sed global private equity firm Perm­ira on the acqui­si­tion of Neur­ax­ph­arm Group in 2020.

Advi­sor Neur­ax­ph­arm Group: Clif­ford Chance
Led by part­ner Dr. Jörg Rhiel (Corporate/Private Equity, Frankfurt).

About Clif­ford Chance

Clif­ford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advi­sors in all major busi­ness centers around the world.
In Germany, Clif­ford Chance is repre­sen­ted by around 300 lawy­ers, audi­tors, tax advi­sors and soli­ci­tors in Düssel­dorf, Frank­furt am Main and Munich.